The original success of Viagra undeniably revolutionized the pharmaceutical landscape, but investing in companies strongly reliant on unbranded versions presents a challenging picture. While early earnings were significant, the end of patents and the appearance of discounted alternatives have weakened sales. Consequently, a thorough assessment of c